Business Context and Reporting Period
The provided filing is MultiPlan Corporation’s unaudited Form 10-Q for the quarter and six months ended June 30, 2023; it does not identify the registrant as Claritev Corp. MultiPlan provides data analytics and technology-enabled healthcare cost-management, payment-accuracy, network, and revenue-integrity services to healthcare payors in the United States. The company operates as one reportable segment.
Financial Performance and Position
| Metric | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 |
|---|---|---|---|---|
| Revenue | $238.0 million | $290.1 million | $474.6 million | $588.2 million |
| Operating income | $34.7 million | $97.8 million | $81.7 million | $214.4 million |
| Net income (loss) | $(36.4) million | $13.5 million | $(36.2) million | $57.5 million |
| Adjusted EBITDA | $152.7 million | $209.6 million | $308.9 million | $435.0 million |
| Cash flow from operations | Not separately provided | Not separately provided | $71.9 million | $235.6 million |
- Quarterly revenue declined 18.0%; six-month revenue declined 19.3%.
- Quarterly operating margin was approximately 14.6%, versus 33.7% in the prior-year quarter. Six-month operating margin was approximately 17.2%, versus 36.5%.
- Quarterly net margin was approximately negative 15.3%, versus positive 4.7% in the prior-year quarter. Six-month net margin was approximately negative 7.6%, versus positive 9.8%.
- Adjusted EBITDA margin was approximately 64.2% for the quarter and 65.1% for the six months, compared with approximately 72.3% and 73.9%, respectively, in the comparable prior periods.
- Cash, cash equivalents, and restricted cash totaled $95.9 million at June 30, 2023, including $89.8 million of unrestricted cash and cash equivalents. Revolver availability was $448.2 million, subject to the facility’s terms; $1.8 million was used for letters of credit.
- Net long-term debt was $4.604 billion at June 30, 2023, compared with $4.742 billion at December 31, 2022. The reported annualized weighted-average cash interest rate was 6.91% at June 30, 2023, compared with 5.80% at June 30, 2022.
- Cash interest paid during the first six months was $161.5 million. Capital expenditures and capitalized software spending were $55.1 million.
Material Changes Versus the Prior Comparable Period
- All three service categories declined in the second quarter: Network-Based Services decreased 9.9%, Analytics-Based Services decreased 21.7%, and Payment and Revenue Integrity Services decreased 12.0%. For the six months, the decreases were 13.4%, 22.0%, and 15.5%, respectively.
- Management attributed the revenue decline primarily to lower medical cost savings on percentage-of-savings claims and contractual rate changes. Six-month potential medical cost savings declined 1.8% to $11.2 billion, while total medical charges processed increased 6.8% to $82.8 billion.
- Costs of services increased 18.1% in the quarter and 17.3% for the six months, primarily because of higher personnel, compensation, claims-processing, and access and bill-review costs.
- Interest expense increased 13.5% in the quarter and 15.1% for the six months, principally because of higher rates on Term Loan B. Term Loan B carried a 9.73% interest rate at June 30, 2023.
- The company repurchased and cancelled $137.8 million principal amount of 5.750% Notes during the six months, recording a $36.8 million gain on extinguishment of debt.
- Operating cash flow fell 69.5% to $71.9 million, reflecting lower earnings, less favorable working-capital changes, and lower non-cash adjustments.
- The company acquired Benefits Science LLC, or BST, on May 8, 2023, for total consideration of approximately $161.2 million, including $141.3 million of cash and $19.2 million of Class A common stock. BST contributed $2.1 million of revenue through June 30, 2023, and the acquisition generated $6.8 million of transaction costs.
Guidance, Outlook, Commentary, Risks, and Unusual Items
- Management stated that cash on hand, operating cash generation, and revolver availability are expected to provide sufficient liquidity for working capital, capital expenditures, and other requirements for at least the next twelve months. The filing does not provide quantitative revenue or earnings guidance.
- The company transitioned its variable-rate debt reference rate from LIBOR to Term SOFR effective July 1, 2023. The filing states that the accounting adoption had no financial-statement impact.
- Management identified risks related to customer concentration, healthcare utilization trends, pricing pressure, provider discounts and relationships, competition, acquisitions and integration, cybersecurity, regulatory and privacy requirements, litigation, personnel retention, credit ratings, and the ability to service substantial debt.
- Three customers represented 32%, 20%, and 10% of 2022 revenue, respectively, creating material customer-concentration risk.
- The company was in compliance with its debt covenants at June 30, 2023. Its consolidated first-lien debt-to-consolidated-EBITDA ratio was 3.54x, compared with 2.64x at December 31, 2022.
- The company authorized up to $100 million of Class A common-stock repurchases through December 31, 2023 and had spent $13.1 million through June 30, 2023. It repurchased 7.1 million shares during the second quarter at an average price of $1.04 per share.
- The Delaware stockholder litigation related to the 2020 business combination was settled and became final in 2023. The company and its insurers paid $33.75 million under the settlement and the company incurred related legal expenses.
- No impairment charges were recorded during the first six months of 2023; the company recorded $662.2 million of impairment charges in fiscal 2022.
- Disclosure controls and procedures were reported effective at June 30, 2023, with no material changes in internal control over financial reporting during the six months.
Important Facts for Investors to Verify
- Confirm the issuer identity: the provided filing is for MultiPlan Corporation, not Claritev Corp.
- Assess whether the sharp revenue decline, lower potential savings, and increased service costs are temporary or structural.
- Evaluate liquidity and debt-service capacity given $4.6 billion of net long-term debt, higher variable interest rates, and substantially lower operating cash flow.
- Review the terms and integration progress of the BST acquisition, including the preliminary $124.2 million goodwill allocation and potential retention payments of up to $82.5 million.
- Reconcile GAAP losses with Adjusted EBITDA and Adjusted EPS, and consider the exclusions for amortization, transaction costs, debt extinguishment gains, stock compensation, and warrant remeasurement.
- Monitor customer concentration, medical-cost-savings trends, healthcare utilization, contractual pricing changes, and the company’s ability to retain providers and major payors.
- Verify future effects of the LIBOR-to-Term-SOFR transition and the company’s compliance with leverage and other debt covenants.